In the field of musculoskeletal care as well as anaesthetic medicine, platelet-rich fibrin (PRF) has recently emerged as a cutting-edge and successful product. The only platelet-based product so far available for treating tissue injury was platelet-rich plasma (PRP).
PlasmoLifting Technology manufactures high quality PRP-tubes, which is the core product of this company that has been successfully used by several physicians worldwide for different therapeutic purposes.
One of the most frequent queries that people often make regarding boosters for quicker soft and hard tissue repair. The quick answer is PRF. Advantages that PRF offers as compared to PRP are as follows:
- Much better simplicity of production
- Absence of any blood manipulation
- No additives
- PRF can produce a bigger share of blood product over the blood share taken
- Contains much more healing factors
- More stem cells and less trauma.
PRP vs PRF:
Although platelet-rich fibrin and platelet-rich plasma share certain fundamental similarities, platelet-rich fibrin stands out as a better therapy option due to few differences.
Both of these items require the patient to give blood. Compared to PRF, PRP requires more blood to be drawn. The full blood sample for each of the products must be put into a centrifuge, where it is treated to help separate the blood into several layers.
When platelet-rich plasma is spun more quickly, all of the blood’s heavier cells, like white blood cells and stem cells, end up accumulating in the test tube’s bottom while the test tube’s top fills with the lighter platelets and plasma.
The tissue-damaged area is subsequently treated with an injection of platelets and plasma that was previously collected from the test tube’s upper portion. A platelet product with an even higher concentration of platelets, as well as a concentration of certain white blood cells and stem cells, is more effective than conventional platelet-rich plasma, according to more recent study.
It was possible to produce platelet-rich fibrin using this new knowledge. The PRF product is spun at a slower speed to prevent a clear separation of the blood layers. As a result, some white blood cells and stem cells can still be found in the platelet layer that is gathered for medical therapy.
As a result, PRF contains more healing components than are generally found in PRP. Additionally, the decreased spin speed results in less damage to the blood’s individual cells, preserving more stem cells in the finished PRF product.
The end product’s platelet concentration is another obvious distinction between platelet-rich fibrin and platelet-rich plasma.
One other distinction between platelet-rich plasma and platelet-rich fibrin is that no anticoagulant is employed when processing blood in the case of PRF. When making platelet-rich plasma, the blood is drawn and put into test tubes with acid citrate dextrose (ACD), an anticoagulant that prevents the blood product from clotting too soon.
The platelet-rich fibrin test tubes lack any anticoagulant to preserve the platelet product’s natural state as much as feasible. In the early phases of clot formation, thrombin converts the natural fibrinogen within human blood to fibrin without the use of any anticoagulant in the test tubes.
As a result, a spongy fibrin matrix is produced, activating the platelets and enabling the gradual release of growth factors that initiates the repair of the tissue.
